Bimekizumab
Bimekizumab (INN[1]) is a monoclonal antibody that is being investigated for ankylosing spondylitis psoriatic arthritis and psoriasis.
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized |
Target | IL17a, IL17f |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
UNII | |
KEGG |
This drug is being developed by Belgian pharmaceutical UCB. As of 2018, bimekizumab is undergoing Phase III trials.
References
- World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 110" (PDF). WHO Drug Information. 27 (4).
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.